Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events

• DOI: 10.1001/jamanetworkopen.2022.45720
• Publication Date: 2022-12-08T16:01:26Z
• Authors: Alexis F. Guédon; Jean-Baptiste De ...; Tristan Mirault; Nassim Mohamedi; Bastien Rance; Natalie Fournier; Jean-Louis Paul; Emmanuel Messas; Guillaume Goudot
• Keywords: Lipoprotein(a); Stroke; Critical limb ischemia

High lipoprotein(a) (Lp[a]) levels are involved in the development of cardiovascular events, particularly myocardial infarction, stroke, and peripheral artery disease. Studies assessing Lp(a) associated with adverse lower-limb events lacking.To assess association between incidence major limb unselected hospitalized patients.This large retrospective monocentric cohort study was conducted from January 1, 2000, to December 31, 2020. Data were derived clinical information system Hôpital Européen Georges-Pompidou, a Paris-based university hospital. Patients who underwent at least 1 measurement center during period included. had no follow-up data or first after outcome occurred excluded. analyses performed May 2021 2022.The primary inpatient event, defined as amputation, endovascular revascularization, surgical follow-up. Secondary outcomes included individual components outcome. Lipoprotein(a) categorized follows: normal (<50 mg/dL), high (50 <134 very (≥134 mg/dL); convert values milligrams per liter, multiply by 0.1.A total 16 513 patients (median [IQR] age, 58.2 [49.0-66.7] years; 9774 men [59.2%]) cohort. The median (IQR) level 24 (10.0-60.0) mg/dL. 1-year event 2.44% overall population 4.54% among levels. (adjusted accelerated failure time [AFT] exponential estimate: 0.43; 95% CI, 0.24-0.78; Benjamini-Hochberg-corrected P = .01) AFT 0.17; 0.07-0.40; < .001) independently an increased risk event.Results this showed that higher patients. needs be taken into account improve vascular assessment.